Detalhe da pesquisa
1.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 23(1): 91-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895487
2.
Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look.
Biol Blood Marrow Transplant
; 26(8): e198-e201, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32304873
3.
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.
Biol Blood Marrow Transplant
; 26(10): 1930-1936, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32649981
4.
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
Br J Haematol
; 190(4): 573-582, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32314807
5.
Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
Blood
; 131(7): 771-781, 2018 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29180399
6.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.
J Natl Compr Canc Netw
; 18(11): 1460-1467, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152703
7.
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
J Natl Compr Canc Netw
; 18(5): 522-536, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32380458
8.
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Lancet Oncol
; 20(8): 1160-1170, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31253572
9.
Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 25(10): 1993-2001, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31229641
10.
Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.
Biol Blood Marrow Transplant
; 25(6): 1122-1127, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30599207
11.
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 25(6): 1107-1115, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30716453
12.
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
Br J Haematol
; 184(5): 744-752, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30520026
13.
Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis.
Biol Blood Marrow Transplant
; 24(4): 827-831, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29155319
14.
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
Biol Blood Marrow Transplant
; 24(10): 2017-2024, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29933073
15.
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
Biol Blood Marrow Transplant
; 24(6): 1163-1171, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242111
16.
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
J Natl Compr Canc Netw
; 16(2): 123-135, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439173
17.
Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.
Curr Oncol Rep
; 20(4): 33, 2018 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29572581
18.
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Br J Haematol
; 175(2): 275-280, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27443247
19.
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Br J Haematol
; 173(3): 404-12, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26953041
20.
Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.
Biol Blood Marrow Transplant
; 21(8): 1529-1531, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25937397